Aragon Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-56021927 capsuleDrug: JNJ-56021927 tablet
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02031666
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Phase 3
Active, not recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 1207
- Registration Number
- NCT01946204
14C-ARN-509 Microtracer Label AME and Absolute BA Study
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01822041
- Locations
- 🇳🇱
PRA - Clinical Research Unit, University Medical Centre Groningen, Groningen, Netherlands
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01792687
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01790126
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Phase 1
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: ARN-509 (Phase 1)Drug: ARN-509 (Phase 2)
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT01171898
© Copyright 2025. All Rights Reserved by MedPath